Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Rating of “Hold” from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have received a consensus recommendation of “Hold” from the eight research firms that are currently covering the stock, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a hold rating. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $19.40.

Several research analysts recently commented on the company. B. Riley Financial lifted their price target on Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 7th. HC Wainwright downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating and upped their price objective for the company from $15.00 to $17.00 in a research report on Tuesday. BTIG Research lowered Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Monday, June 29th. Zacks Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, June 8th. Finally, TD Cowen boosted their target price on Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a research report on Monday, March 23rd.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 13,314 shares of the business’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $16.39, for a total transaction of $218,216.46. Following the transaction, the senior vice president owned 232,457 shares in the company, valued at $3,809,970.23. The trade was a 5.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Eli Samaha sold 37,799 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $17.00, for a total transaction of $642,583.00. Following the completion of the sale, the insider directly owned 9,174,453 shares in the company, valued at approximately $155,965,701. This represents a 0.41% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 350,011 shares of company stock valued at $6,008,309. 7.65% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Theravance Biopharma

A number of large investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Theravance Biopharma by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock valued at $32,289,000 after purchasing an additional 54,152 shares during the last quarter. State Street Corp boosted its position in shares of Theravance Biopharma by 4.4% during the fourth quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company’s stock valued at $20,616,000 after buying an additional 45,987 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Theravance Biopharma by 14.5% during the first quarter. Dimensional Fund Advisors LP now owns 983,615 shares of the biopharmaceutical company’s stock valued at $15,960,000 after buying an additional 124,658 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Theravance Biopharma by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company’s stock valued at $17,567,000 after buying an additional 40,734 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Theravance Biopharma in the third quarter worth approximately $10,611,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Stock Down 0.1%

TBPH stock opened at $17.00 on Thursday. Theravance Biopharma has a 52 week low of $10.82 and a 52 week high of $21.03. The firm has a market capitalization of $876.35 million, a P/E ratio of 7.73 and a beta of 0.17. The company has a fifty day simple moving average of $16.61 and a two-hundred day simple moving average of $17.25.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share for the quarter. The business had revenue of $17.70 million during the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. As a group, analysts anticipate that Theravance Biopharma will post 1.54 EPS for the current year.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.